|
US6828415B2
(en)
*
|
1993-02-19 |
2004-12-07 |
Zentaris Gmbh |
Oligopeptide lyophilisate, their preparation and use
|
|
CA2355186C
(en)
*
|
1998-12-15 |
2008-03-18 |
Takeda Pharmaceutical Company Limited |
Process for producing polymer
|
|
CN1361685A
(zh)
*
|
1999-07-15 |
2002-07-31 |
武田药品工业株式会社 |
缓释组合物、其制备方法和用途
|
|
CA2412899C
(en)
|
2000-07-05 |
2010-11-09 |
Takeda Chemical Industries, Ltd. |
Medicinal preparations for treating sex hormone-dependent diseases
|
|
DK1310517T4
(da)
†
|
2000-08-07 |
2011-01-17 |
Wako Pure Chem Ind Ltd |
Mælkesyrepolymer og fremgangsmåde til fremstilling af denne
|
|
DE10040700A1
(de)
*
|
2000-08-17 |
2002-02-28 |
Asta Medica Ag |
Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
|
|
WO2002043766A1
(en)
*
|
2000-11-29 |
2002-06-06 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions and process for producing the same
|
|
WO2002047722A1
(en)
*
|
2000-12-15 |
2002-06-20 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
|
|
US20040116522A1
(en)
*
|
2001-03-30 |
2004-06-17 |
Yutaka Yamagata |
Medicinal solutions
|
|
EP1382350A4
(en)
*
|
2001-04-25 |
2006-01-04 |
Takeda Pharmaceutical |
MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
|
|
TWI225416B
(en)
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
|
TWI332407B
(en)
*
|
2001-06-29 |
2010-11-01 |
Takeda Chemical Industries Ltd |
Controlled release composition and method of producting the same
|
|
WO2003015820A1
(en)
*
|
2001-08-10 |
2003-02-27 |
Takeda Chemical Industries, Ltd. |
GnRH AGONIST COMBINATION DRUGS
|
|
ES2541908T3
(es)
*
|
2001-10-10 |
2015-07-28 |
Pierre Fabre Medicament |
Microesferas biodegradables de liberación prolongada y su procedimiento de preparación
|
|
CA2466659A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticancer agents
|
|
US20050064039A1
(en)
*
|
2001-12-26 |
2005-03-24 |
Tomomichi Futo |
Novel microsphere and method for production thereof
|
|
US7674232B2
(en)
|
2002-04-19 |
2010-03-09 |
Pelikan Technologies, Inc. |
Method and apparatus for penetrating tissue
|
|
US7175642B2
(en)
|
2002-04-19 |
2007-02-13 |
Pelikan Technologies, Inc. |
Methods and apparatus for lancet actuation
|
|
DK1532985T3
(en)
*
|
2002-06-25 |
2016-12-05 |
Takeda Pharmaceuticals Co |
PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
|
|
RU2329274C2
(ru)
*
|
2002-09-11 |
2008-07-20 |
Фрезениус Каби Дойчланд Гмбх |
Способ получения производных гидроксиалкилкрахмала
|
|
US7202326B2
(en)
*
|
2002-09-24 |
2007-04-10 |
Asahi Kasei Chemicals Corporation |
Glycolic acid copolymer and method for production thereof
|
|
US6962006B2
(en)
*
|
2002-12-19 |
2005-11-08 |
Acusphere, Inc. |
Methods and apparatus for making particles using spray dryer and in-line jet mill
|
|
BRPI0409032A
(pt)
|
2003-04-10 |
2006-05-02 |
Pr Pharmaceuticals |
método para a produção de micropartìculas à base de emulsão
|
|
US20070207211A1
(en)
*
|
2003-04-10 |
2007-09-06 |
Pr Pharmaceuticals, Inc. |
Emulsion-based microparticles and methods for the production thereof
|
|
CN102935069A
(zh)
*
|
2003-07-15 |
2013-02-20 |
Pr药品有限公司 |
控释组合物的制备方法
|
|
US8900636B2
(en)
|
2003-07-23 |
2014-12-02 |
Evonik Corporation |
Controlled release compositions
|
|
AU2004279438A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Inverseon, Inc. |
Methods for treating diseases and conditions with inverse agonists
|
|
US20070276024A1
(en)
*
|
2003-10-09 |
2007-11-29 |
Inverseon , Inc. |
Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
|
|
TW200529890A
(en)
*
|
2004-02-10 |
2005-09-16 |
Takeda Pharmaceutical |
Sustained-release preparations
|
|
TW200613012A
(en)
*
|
2004-07-02 |
2006-05-01 |
Takeda Pharmaceuticals Co |
Sustained-release composition, process for producing the same and use of the same
|
|
US7528175B2
(en)
*
|
2004-10-08 |
2009-05-05 |
Inverseon, Inc. |
Method of treating airway diseases with beta-adrenergic inverse agonists
|
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
|
US20060222716A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Joseph Schwarz |
Colloidal solid lipid vehicle for pharmaceutical use
|
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
ATE382337T1
(de)
*
|
2005-04-28 |
2008-01-15 |
Nipro Corp |
Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
|
|
US20070027107A1
(en)
*
|
2005-07-29 |
2007-02-01 |
Curt Hendrix |
Compositions and methods for treating estrogen-dependent diseases and conditions
|
|
AU2006332340B2
(en)
|
2005-12-30 |
2013-09-26 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
|
BRPI0708879A2
(pt)
*
|
2006-03-13 |
2011-06-14 |
Encysive Pharmaceuticals |
peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
|
|
KR101419554B1
(ko)
*
|
2006-03-13 |
2014-07-17 |
교린 세이야꾸 가부시키 가이샤 |
Gsk3 억제제로서 아미노퀴놀론
|
|
EP2001446A2
(en)
*
|
2006-03-13 |
2008-12-17 |
Encysive Pharmaceuticals, Inc |
Formulations of sitaxsentan sodium
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
TWI481424B
(zh)
*
|
2006-12-18 |
2015-04-21 |
Takeda Pharmaceutical |
緩釋性組成物及其製法
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
RU2343908C1
(ru)
*
|
2007-09-05 |
2009-01-20 |
Руслан Дмитриевич Илюк |
Средство для профилактики и лечения алкоголизма и способ его применения
|
|
BRPI0816798A2
(pt)
*
|
2007-09-11 |
2016-10-11 |
Activx Biosciences Inc |
composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
|
|
CN101855229A
(zh)
|
2007-09-12 |
2010-10-06 |
埃迪威克斯生物科学公司 |
作为gsk-3抑制剂的螺环状氨基喹诺酮
|
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
|
PL2401267T3
(pl)
|
2009-02-27 |
2014-06-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
|
|
BRPI1008974A2
(pt)
|
2009-03-11 |
2017-06-06 |
Kyorin Seiyaku Kk |
composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
|
|
BR112012003661A2
(pt)
|
2009-08-19 |
2017-04-25 |
Ambit Biosciences Corp |
"compostos de biarila e métodos de uso dos mesmos."
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
CN103298805A
(zh)
|
2010-09-01 |
2013-09-11 |
埃姆比特生物科学公司 |
喹唑啉化合物及其使用方法
|
|
WO2012082521A2
(en)
*
|
2010-12-15 |
2012-06-21 |
3M Innovative Properties Company |
Degradable fibers
|
|
WO2012096866A2
(en)
|
2011-01-10 |
2012-07-19 |
Inverseon, Inc. |
Use of beta-adrenergic inverse agonists for smoking cessation
|
|
AR082266A1
(es)
*
|
2011-05-13 |
2012-11-28 |
Univ Nac Del Litoral |
Microparticula inyectable de liberacion controlada
|
|
JP2014517076A
(ja)
|
2011-06-23 |
2014-07-17 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
新規のフルオロエルゴリン類似体
|
|
CA2851155C
(en)
|
2011-10-14 |
2021-02-23 |
Ambit Biosciences Corporation |
Heterocyclic compounds and methods of use thereof
|
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
EP3039021A1
(en)
|
2013-08-30 |
2016-07-06 |
Ambit Biosciences Corporation |
Biaryl acetamide compounds and methods of use thereof
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
TW201618783A
(zh)
|
2014-08-07 |
2016-06-01 |
艾森塔製藥公司 |
以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
|
|
CN106999593A
(zh)
|
2014-09-12 |
2017-08-01 |
妥必徕疗治公司 |
用于纤维化治疗的赛尼克韦罗组合疗法
|
|
WO2016065264A1
(en)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
イソエルゴリン化合物およびその使用
|
|
WO2016118541A1
(en)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
|
JP6630742B2
(ja)
|
2015-08-17 |
2020-01-15 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CA3006966A1
(en)
|
2015-12-02 |
2017-06-08 |
Astraea Therapeutics, Llc |
Piperidinyl nociceptin receptor compounds
|
|
JP7009371B2
(ja)
|
2015-12-29 |
2022-01-25 |
ガルデルマ エス.エー. |
バイオポリマーを脱アセチル化するための方法
|
|
WO2017120415A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
BR112018013761A2
(pt)
|
2016-01-08 |
2018-12-11 |
Celgene Corp |
compostos antiproliferativos e suas composições farmacêuticas e usos
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
EP3534885B1
(en)
|
2016-11-03 |
2021-01-20 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in treating cancer
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
KR20200090982A
(ko)
|
2017-02-21 |
2020-07-29 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
MX2019014272A
(es)
|
2017-06-01 |
2020-12-11 |
Xoc Pharmaceuticals Inc |
Compuestos policiclicos y usos de los mismos.
|
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US12391705B2
(en)
|
2018-12-19 |
2025-08-19 |
Shy Therapeutics, Llc |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
JP7641232B2
(ja)
|
2019-03-29 |
2025-03-06 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Il-17aモジュレーターおよびその使用
|
|
CA3179635A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
EP4168414A1
(en)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
EP4149471A4
(en)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences, Inc. |
ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
|
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
WO2022192545A1
(en)
|
2021-03-10 |
2022-09-15 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
US12017997B2
(en)
|
2021-10-22 |
2024-06-25 |
Prosetta Biosciences, Inc. |
Host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
KR102709458B1
(ko)
*
|
2021-11-23 |
2024-09-23 |
한국화학연구원 |
서방출 클로니딘 미립구형 주사제 및 그의 제조방법
|
|
AU2022399572A1
(en)
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
WO2023129576A2
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
JP2025508811A
(ja)
*
|
2022-02-22 |
2025-04-10 |
上海雲晟研新生物科技有限公司 |
カリプラジン薬用塩及びその結晶形、医薬組成物、製造方法並びに使用
|
|
US12168673B2
(en)
|
2022-03-02 |
2024-12-17 |
Mitopower, Inc. |
Prodrugs derived from nicotinic acid and ribose
|
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
US12187699B2
(en)
|
2022-04-14 |
2025-01-07 |
Bristol-Myers Squibb Company |
GSPT1 compounds and methods of use of the novel compounds
|
|
CN119156456A
(zh)
|
2022-04-15 |
2024-12-17 |
新基公司 |
预测淋巴瘤对药物的反应性的方法以及治疗淋巴瘤的方法
|
|
EP4519439A1
(en)
|
2022-05-05 |
2025-03-12 |
BioMarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
KR20250099113A
(ko)
|
2022-09-09 |
2025-07-01 |
이노보 테라퓨틱스 인코포레이티드 |
CK1α 및 DUAL CK1α/GSPT1 분해 화합물
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
EP4608839A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
EP4608834A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
EP4626865A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
EP4702143A2
(en)
|
2023-04-24 |
2026-03-04 |
BioMarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
US20240368596A1
(en)
|
2023-05-05 |
2024-11-07 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
TW202530223A
(zh)
|
2023-09-27 |
2025-08-01 |
美商艾索司特瑞克斯公司 |
Myst抑制劑
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|